Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

被引：0
|
作者：
Lorraine Dalens
Julie Niogret
Corentin Richard
Sandy Chevrier
Pascal Foucher
Bruno Coudert
Aurélie Lagrange
Laure Favier
Virginie Westeel
Stefano Kim
Olivier Adotevi
Caroline Chapusot
Laurent Martin
Laurent Arnould
Courèche-Guillaume Kaderbhai
Romain Boidot
机构：
[1] Georges-François Leclerc Cancer Center – UNICANCER,Medical Oncology Department
[2] Georges-François Leclerc Cancer Center – UNICANCER,Molecular Biology Unit, Department of Biology and Pathology of Tumors
[3] Dijon University Hospital,Department of Thoracic Oncology
[4] University Hospital of Besançon,Chest Disease Department
[5] Dijon University Hospital,Department of Pathology
[6] Georges-François Leclerc Cancer Center – UNICANCER,Pathology Unit, Department of Biology and Pathology of Tumors
[7] UMR CNRS 6302,undefined
来源：
Molecular Cancer | / 22卷
关键词：
Lung carcinoma; Exome analysis; SNPs; Innate immunity; EGFR TKI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 23 条
  • [1] Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes
    Dalens, Lorraine
    Niogret, Julie
    Richard, Corentin
    Chevrier, Sandy
    Foucher, Pascal
    Coudert, Bruno
    Lagrange, Aurelie
    Favier, Laure
    Westeel, Virginie
    Kim, Stefano
    Adotevi, Olivier
    Chapusot, Caroline
    Martin, Laurent
    Arnould, Laurent
    Kaderbhai, Coureche-Guillaume
    Boidot, Romain
    MOLECULAR CANCER, 2023, 22 (01)
  • [2] Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms
    Ryo Ariyasu
    Noriko Yanagitani
    Kenichi Tadokoro
    Toshikazu Yamaguchi
    Ken Uchibori
    Satoru Kitazono
    Naoya Fujita
    Ryohei Katayama
    Makoto Nishio
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 517 - 525
  • [3] Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms
    Ariyasu, Ryo
    Yanagitani, Noriko
    Tadokoro, Kenichi
    Yamaguchi, Toshikazu
    Uchibori, Ken
    Kitazono, Satoru
    Fujita, Naoya
    Katayama, Ryohei
    Nishio, Makoto
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (04) : 517 - 525
  • [4] Expression of Mismatch Repair Proteins Associates with Survival and Response to EGFR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Patients
    Ho, H.
    Yeh, Y.
    Hsieh, W.
    Chou, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1926 - S1926
  • [5] Lack of response to EGFR tyrosine kinase inhibitors in an amylase-producing lung cancer with a preexisting MET amplification
    Nemoto, Kenji
    Hayashihara, Kenji
    Oh-ishi, Shuji
    Nakazawa, Mariko
    Fujita, Kazutaka
    Sakurai, Hirofumi
    Kanazawa, Jun
    Shih-Yuan, Lin
    Takaku, Takio
    Minami, Yuko
    Saito, Takefumi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2015, 4 (04): : 236 - 240
  • [6] Lack of response to EGFR tyrosine kinase inhibitors in an amylase-producing lung cancer with a preexisting MET amplification
    Kenji Nemoto
    Kenji Hayashihara
    Shuji Oh-ishi
    Mariko Nakazawa
    Kazutaka Fujita
    Hirofumi Sakurai
    Jun Kanazawa
    Lin Shih-Yuan
    Takio Takaku
    Yuko Minami
    Takefumi Saito
    International Cancer Conference Journal, 2015, 4 (4) : 236 - 240
  • [7] Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer
    Zheng, Zhi S.
    Xia, Bing
    Xie, Rui F.
    Li, Xia D.
    Zhu, Jue
    Wu, Shi X.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S548
  • [8] RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
    Chunyue Wang
    Zhenlong Zhang
    Yulan Sun
    Song Wang
    Mengmeng Wu
    Qiuxiang Ou
    Yang Xu
    Zhiming Chen
    Yang Shao
    Hong Liu
    Peifeng Hou
    Journal of Translational Medicine, 20
  • [9] RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
    Wang, Chunyue
    Zhang, Zhenlong
    Sun, Yulan
    Wang, Song
    Wu, Mengmeng
    Ou, Qiuxiang
    Xu, Yang
    Chen, Zhiming
    Shao, Yang
    Liu, Hong
    Hou, Peifeng
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [10] The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
    Gou, Lan-Ying
    Li, An-Na
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Su, Jian
    Yan, Hong-Hong
    Xie, Zhi
    Lou, Na-Na
    Liu, Si-Yang
    Dong, Zhong-Yi
    Gao, Hong-Fei
    Zhou, Qing
    Zhong, Wen-Zhao
    Xu, Chong-Rui
    Wu, Yi-Long
    ONCOTARGET, 2016, 7 (32) : 51311 - 51319
123